<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04633369</url>
  </required_header>
  <id_info>
    <org_study_id>MHO-0488-20</org_study_id>
    <nct_id>NCT04633369</nct_id>
  </id_info>
  <brief_title>The Role of the Microbiome in the Response to Dietary Fibers Intake During Intermediate Fasting</brief_title>
  <official_title>The Role of the Microbiome and Host Physiology in Personalized Human Response to Dietary Fibers Intake During Intermediate Fasting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weizmann Institute of Science</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Weizmann Institute of Science</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dietary fibers are generally not degraded by the endogenous digestive enzymes, but rather by&#xD;
      the complex ensemble of microorganisms that reside in the human gut [1]. This ensemble,&#xD;
      collectively known as the human gut microbiome, plays a key role in breaking down,&#xD;
      fermenting, and ultimately converting such dietary fibers into a variety of beneficial&#xD;
      metabolites, including most notably, short chain fatty acids (SCFA). These end products of&#xD;
      fibers' fermentation affect host metabolism, immunity, and physiology, and have been&#xD;
      implicated in multiple diseases including obesity, metabolic syndrome, diabetes, and&#xD;
      cardiovascular diseases.&#xD;
&#xD;
      Intermediate fasting, and in particular circadian intermediate fasting (i.e. 16 hours of&#xD;
      fasting followed by 8 hours of allowed eating), has been shown to have positive associations&#xD;
      with multiple health conditions as obesity, diabetes mellitus, cardiovascular disease,&#xD;
      cancers, and neurologic disorders In this study, we will try to answer open questions&#xD;
      utilizing the long fasting period during the day to investigate the isolated effect of&#xD;
      dietary fiber consumption, uncovering the degradation effect, but not the bulking effect, on&#xD;
      the microbiome and the host physiology, and in particular its glucose response.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During the 22 days of the study, participants will wear a continuous glucose monitor, fill a&#xD;
      daily food diary, and collect stool and oral samples which will be used for microbiota&#xD;
      profiling. Participants will be asked to carry out an intermediate fasting regime, which will&#xD;
      include: 16 straight hours of fasting followed by 8 hours which the participants will be&#xD;
      allowed to eat. Drinking water is allowed throughout the fasting hours.&#xD;
&#xD;
      The groups will consume 4, 12, 20 grams of the dietary fiber per day, according to the group&#xD;
      they were assigned to, while not exceeding the total fiber consumption of 50 grams per day,&#xD;
      which is considered a high-fiber diet.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 21, 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>microbiome</measure>
    <time_frame>1 year</time_frame>
    <description>stool and oral samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>glycemic response of different dietary fibers</measure>
    <time_frame>1 year</time_frame>
    <description>Continuous glucose monitoring (CGM)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Dietary Fibers</condition>
  <condition>Intermediate Fasting</condition>
  <arm_group>
    <arm_group_label>Fructo-oligosaccharide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fructo-oligosaccharide 20g</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arabinogalactan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arabinogalactan 12g</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucomannan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glucomannan 4g</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>dietary fibers</intervention_name>
    <description>during days 13-22 the participants will consume the dietary fiber according to their randomization and continue fasting. Participants will be asked to collect stool and oral samples 4 times during this period.</description>
    <arm_group_label>Arabinogalactan</arm_group_label>
    <arm_group_label>Fructo-oligosaccharide</arm_group_label>
    <arm_group_label>Glucomannan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Male and Female BMI&lt;28 Age - 18-70&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Consumption of antibiotics 3 months prior to the first day of the experiment. Consumption&#xD;
        of probiotic or dietary fibers supplements 1 month prior to the first day of the&#xD;
        experiment.&#xD;
&#xD;
        Practiced in intermediate fasting 1 month prior to the first day of the experiment.&#xD;
&#xD;
        Diagnosis with type 1 or type 2 diabetes. Pregnancy, breastfeeding, or fertility treatments&#xD;
        in the last 6 months. Chronic disease (e.g. AIDS, Cushing syndrome, CKD, acromegaly,&#xD;
        hyperthyroidism hepatitis, fibromyalgia, etc.).&#xD;
&#xD;
        Cancer and recent anticancer treatment. Psychiatric disorders. Coagulation disorders. IBD&#xD;
        (inflammatory bowel diseases). IBS (Irritable bowel syndrome). Alcohol abuse, more than 2&#xD;
        drinks per day for males, and more than one drink for females.&#xD;
&#xD;
        Substance abuse. BMI&gt;28. Daily dietary intake higher than 25 grams per day. History of&#xD;
        abdominal surgeries (including Bariatric surgery). Mentally incompetent or lack of judgment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eran Elinav, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weizmann Institute of Science</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aurelie Bukimer, Bsc</last_name>
    <phone>+97289529173</phone>
    <email>aurelie.bukimer@weizmann.ac.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Weizmann institute of science</name>
      <address>
        <city>Reáº–ovot</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurelie Bukimer</last_name>
      <phone>97289346745</phone>
      <email>aurelie.bukimer@weizmann.ac.il</email>
    </contact>
    <contact_backup>
      <last_name>Ruth Fischbein</last_name>
      <email>ruthy.fischbein@weizmann.ac.il</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 12, 2020</study_first_submitted>
  <study_first_submitted_qc>November 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2020</study_first_posted>
  <last_update_submitted>September 12, 2021</last_update_submitted>
  <last_update_submitted_qc>September 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

